Table 1.
Patient characteristics in this study (n = 141).
Table 2.
Efficacy of Treatment in the ED-SCLC patients (n = 141).
Fig 1.
Kaplan–Meier analysis of overall survival (OS) in group 1 (blue) vs. group 2 (green) vs. group 3 (red) vs. group 4 (yellow).
P values were determined using the log-rank test; the number of individuals in each group and median survival [95% confidence interval (CI)] are indicated. Group 1 included patients with a solitary metastatic site in one organ, group 2 patients with 2–5 metastatic sites in one organ, group 3 those with ≥6 metastases in one organ, and group 4 those with ≥2 organs with metastases. M; months.
Fig 2.
Kaplan–Meier analyses of progression-free survival (PFS) (A) and overall survival (OS) (B) of patients with oligometastases (blue: group 1 and 2) vs. patients with polymetastases (red: group 3 and 4) treated with chemotherapy. P values were determined using the log-rank test; the number of individuals in each group and median survival (95% CI) are indicated. M; months, Oligo; oligometastases, Poly; polymetastases.
Table 3.
Univariate and multivariate analyses for overall survival in the ED-SCLC patients (n = 141).
Fig 3.
Pattern of recurrence in the oligometastatic ED-SCLC patients (n = 49).
43 of 49 (88%) ED-SCLC patients had relapsed after initial chemotherapy. Of the patients who relapsed, 27 (63%) exacerbated primary lung lesion (red), 8 (19%) relapsed at oligometastatic sites (orange) and 3 (7%) relapsed in both the primary and the oligometastatic sites (light orange). 5 (12%) patients had recurrence into new lesions (green).